Innovative dermatology company with a successful track record of two NDA approvals and advanced orphan drugs pipeline

Sol-Gel was successful in developing pioneer topical drugs, Twyneo® and Epsolay®, for the treatment of acne and inflammatory lesions of rosacea. Both products are marketed in the US by Galderma since 2022.

We are developing topical patidegib that is expected to be approved for the treatment of Gorlin syndrome and topical erlotinib for the treatment of pachyonychia congenita and other rare skin indications.

Skip to content